Listen as Cynthia Matossian, MD; and Bret Fisher, MD, share their experiences and advice with regard to improving efficiency in a premium IOL practice.

It's the last episode of 2019 and we're keeping it short! Listen as Justin Kwan, OD, FAAO, describes the potential for virtual reality and augmented reality in eye care (0:56). Want some tips on discussing and dispensing specialty lenses? Steven A. Turpin, OD, explains how one small lens can make a world of difference for your patients and your practice (9:10). In the third and final article in this episode, Leslie O'Dell, OD, FAAO, makes the connection between dry eye, sleep, and poor lid performance (14:14). New for next year: More episodes! That's more content more often in 2020. Check back in January 2020.

With both doctors having the TECNIS Symfony® IOL (Johnson & Johnson Vision) implanted in their own eyes, Michael Shapiro, MD, and Sondra Black, OD, review how their personal experiences influenced their lens recommendations for patients following cataract surgery.

In this episode, Rosa M. Braga-Mele, MD, Med, FRCSC; and Eric D. Donnenfeld, MD, outline the latest IOL technologies that are available in the US and abroad, and discuss what surgeons can expect in this field in the coming years.

In this special Thanksgiving episode of Off the Grid, host Blake Williamson, MD, MPH, and several of his colleagues take a moment to share why they feel thankful to be in ophthalmology and which mentors they are most grateful to have in their lives.

The heterogeneous nature of uveitis makes it a challenging disease to treat. Phoebe Lin, MD, PhD, reviews common mistakes in uveitis management that an AAO panel found worthy of highlighting. And Steven Yeh, MD, discusses which emerging infectious diseases retina specialists need to know about-and what they can do when they encounter them.

Uveal melanoma carries a risk of metastasis, which may occur before the disease is even detected. Moreover, even when uveal melanoma is treated, there's a good chance that the radiation used during therapy will result in radiation retinopathy. Prithvi Mruthyunjaya, MD, MHS, reviews the state of uveal melanoma therapies in clinical trials and discusses how doctors might employ new tactics to prevent metastatic disease. Also, Amy Schefler, MD, outlines a trial examining how patients with radiation retinopathy respond to anti-VEGF therapy. How could this change the visual function of patients whose cancer treatments left them visually impaired?

Brolucizumab (Beovu, Novartis) was approved by the US FDA for the treatment of wet AMD. But how does it affect patients with polypoidal choroidal vasculopathy? Glenn Jaffe, MD, joins the podcast to discuss a substudy in the phase 3 HAWK trial that aimed to find out. Also, as the FDA reviews a new drug application for abicipar pegol (Allergan), what can we learn from the phase 3 trials CEDAR and SEQUOIA now that the 2-year data were released? Rahul Khurana, MD, details his presentation live from the BMC booth.

Diabetic retinopathy may be proliferative or nonproliferative, and patients may present with or without macular edema. And then there's the possibility that one patient's disease is VEGF-mediated whereas another's is not. With all of these factors, it's important to understand which therapeutic options work best for particular patients. Nathan Steinle, MD, reviews data from the BOULEVARD trial, a phase 2 study evaluating faricimab (Genentech/Roche) in patients with DME. And Rishi Singh, MD, parses the 52-week data from the PANORAMA trial, which evaluated the effect of aflibercept (Eylea, Regeneron) in approximately 400 patients with high-risk NPDR without DME.

Robert J. Cionni, MD; Jeffrey D. Horn, MD; and Vance Thompson, MD, discuss their experiences with the only trifocal IOL available to surgeons and patients in the United States. Listen as they share insights into this new era of refractive cataract surgery and how they educate patients about trifocality.